X4 Pharmaceuticals, Inc
corporate_fare Company Profile
X4 Pharmaceuticals, Inc (NASDAQ:XFOR) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 13 items for XFOR at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-09-08, rated 7/10. Across its 13 most recent items scored 7 or higher, the top rating is 9/10, with 6 rated 8 or above. Recent SEC coverage for XFOR spans 8-K, 10-Q, DEFA14A, DEF 14A.
Recent high-impact activity:
- X4 Posts Corporate Presentation With Detailed Phase 2 Data Supporting 4WARD Pivotal Trial
- FDA Agrees to Cut 4WARD Trial Size to 126 Patients, Clearing Path to Faster Data
- FDA Backs Smaller Phase 3 Trial for X4's Chronic Neutropenia Drug
- X4 Pharma Extends Cash Runway to 2029, Advances Phase 3 Trial with FDA Update Expected by Q3 End
- X4 Pharmaceuticals Q2 2026: EU Nod for XOLREMDI and Cash Runway Through 2029
Financial Snapshot
Dilution Risk
Low riskFiling-implied dilution signals for XFOR, detected from its recent SEC filings · based on capital-structure filings through 2026-05-12.
Equity Incentive Plan Expanded · Potential Dilution
⚠ A more recent filing has been published for this ticker since this signal was computed; it may not yet be reflected — see the filings below.
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →